Recent Updates
Recently added Catalysts

LY4292009

Phase 1

Healthy | Small molecule | Other |Eli Lilly and Company|Last Updated: Apr 17, 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedPLACEBO_CONTROLLED
Total Trials1
Total Enrollment80

FDA Designations

No designations recorded

Clinical trial landscape

LY4292009 · 1 trial · 1 indication

Phase 1 1
NCT06977880A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy ParticipantsHealthy
COMPLETED80 Analytics
PHASE1COMPLETED
A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants
Healthy
NCT0697788080
Unlock trial analytics

Study Endpoints

Primary Endpoints

Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Event (SAEs) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)
Baseline to Study Completion (Up to Day 17)
Percentage of Participants with TEAEs and SAEs in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)
Baseline to Study Completion (Up to Day 7)
Number of Participants with One or More Serious Adverse Event(s) (SAEs) in (Cohort A1-A6) and MAD (Cohort B1-B4)
Baseline to Study Completion (Up to Day 7)
Change from Baseline in Laboratory Parameter and Vital Signs in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)
Baseline to Study Completion (Up to Day 7)
Number of Participants with Clinically Significant Changes in Cardiovascular Evaluation in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)
Baseline to Study Completion (Up to Day 7)

Secondary Endpoints

Pharmacokinetics (PK): Maximum Concentration (Cmax) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)
SAD Cohorts: Predose up to Day 4 Postdose
PK: Time to Maximum Concentration (Tmax) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)
SAD Cohorts: Predose up to Day 4 Postdose
PK: Area Under the Concentration Curve (AUC) in SAD (Cohort A1-A6) and MAD (Cohort B1-B4)
SAD Cohorts: Predose up to Day 4 Postdose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingSINGLE
ModelPARALLEL
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Cohort A1EXPERIMENTALParticipants received LY4292009 orally.
Cohort A2EXPERIMENTALParticipants received LY4292009 orally.
Cohort A3EXPERIMENTALParticipants received LY4292009 orally.
Cohort A4EXPERIMENTALParticipants received LY4292009 orally.
Cohort A5EXPERIMENTALParticipants received LY4292009 orally.
Cohort A6 (Optional)EXPERIMENTALParticipants received LY4292009 orally.
Cohort B1EXPERIMENTALParticipants received LY4292009 orally.
Cohort B2EXPERIMENTALParticipants received LY4292009 orally.
Cohort B3EXPERIMENTALParticipants received LY4292009 orally.
Cohort B4 (Optional)EXPERIMENTALParticipants received LY4292009 orally.
PlaceboPLACEBO_COMPARATORParticipants receive placebo.

Interventions

NameTypeDescription
LY4292009DRUGAdministered orally
PlaceboDRUGAdministered orally.
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Body mass index (BMI) within 18.0 kg/m² to 30.0 kg/m², inclusive * If male, meets one of the following: * can procreate and agree to use one of the accepted to use one of the accepted contraceptive regimens and not to donate sperm from the first study drug administration to...

Countries:Canada
Unlock Eligibility Criteria

Frequently asked questions about LY4292009

What is LY4292009?

LY4292009, also known as MORF-440, is an investigational small molecule being developed by Eli Lilly and Company. It is currently in Phase 1 clinical development for use in healthy participants. The drug is being studied as a first-in-human therapy, though its specific therapeutic indication has not been established.

What is LY4292009 used for?

LY4292009 is being studied for use in healthy participants as part of a Phase 1 first-in-human clinical trial. The drug is intended to evaluate safety and tolerability in humans, but its specific therapeutic indication has not been defined. It is an investigational small molecule in early clinical development.

Who makes LY4292009?

LY4292009 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The drug is currently in Phase 1 clinical development and is being studied in a first-in-human trial.

What phase is LY4292009 in?

LY4292009 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in a first-in-human trial to evaluate its safety and tolerability in healthy participants.

What clinical trials is LY4292009 in?

LY4292009 is being studied in one clinical trial, identified as NCT06977880. This is a Phase 1, first-in-human study of MORF-440 (LY4292009) in healthy participants. The trial was conducted in Canada, enrolled 80 participants, and has been completed.

Is LY4292009 the same as MORF-440?

Yes, LY4292009 is also known as MORF-440. The clinical trial NCT06977880 is titled 'A Phase 1, First-in-human Study of MORF-440 (LY4292009) in Healthy Participants,' confirming that both names refer to the same investigational drug being developed by Eli Lilly and Company.